Articles from Cambrian Bio

Cambrian Bio, a clinical-stage drug development company with pipeline therapies targeting the underlying drivers of metabolic decline and dysfunction, today announced that a poster featuring data from two Phase 1 studies of ATX-304 will be presented at ObesityWeek® 2026, The Obesity Society's 44th Annual Meeting, taking place November 14-17, 2026, at the Gaylord National Resort & Convention Center in National Harbor, Maryland.

Cambrian Bio, a clinical-stage drug development company with pipeline therapies targeting critical metabolic pathways that decline with age, today announced the presentation of first human clinical data for ATX-304, an AMP-activated protein kinase (AMPK) Network Activator in clinical development for obesity and other forms of cardiometabolic disease. The data were presented in two poster sessions at the American Diabetes Association’s (ADA) 86th Scientific Sessions that took place June 5–8, 2026, in New Orleans, Louisiana.

Cambrian Bio, a clinical-stage drug development company with pipeline therapies targeting critical metabolic pathways that decline with age, today announced that two posters featuring data on one of its lead pipeline therapeutics, ATX-304, will be presented at the American Diabetes Association’s (“ADA”) 86th Scientific Sessions, taking place June 5-8, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Cambrian Bio will present data from its Phase 1b clinical study of ATX-304 in participants with obesity and prediabetes, as well as further research into the mechanism of action of ATX-304.